stoxline Quote Chart Rank Option Currency Glossary
  
Ocean Biomedical, Inc. (OCEA)
1.34  0.085 (6.77%)    04-26 16:00
Open: 1.26
High: 1.4268
Volume: 246,371
  
Pre. Close: 1.255
Low: 1.26
Market Cap: 46(M)
Technical analysis
2024-04-26 4:43:58 PM
Short term     
Mid term     
Targets 6-month :  3.93 1-year :  5.46
Resists First :  3.36 Second :  4.67
Pivot price 1.86
Supports First :  1.25 Second :  1.04
MAs MA(5) :  1.39 MA(20) :  2.15
MA(100) :  1.69 MA(250) :  3.12
MACD MACD :  -0.5 Signal :  -0.4
%K %D K(14,3) :  3.1 D(3) :  3.4
RSI RSI(14): 28.8
52-week High :  12.07 Low :  0.51
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ OCEA ] has closed above bottom band by 18.4%. Bollinger Bands are 6.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.43 - 1.44 1.44 - 1.45
Low: 1.24 - 1.25 1.25 - 1.26
Close: 1.32 - 1.34 1.34 - 1.36
Company Description

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.

Headline News

Wed, 24 Apr 2024
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K - GlobeNewswire

Mon, 18 Mar 2024
Ocean Biomedical: Shooting Upward, But Not Somewhere I Want To Be (Rating Upgrade) (OCEA) - Seeking Alpha

Fri, 08 Mar 2024
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview - XM

Thu, 07 Mar 2024
Ocean Biomedical Inc options imply 31.8% move in share price post-earnings - TipRanks.com - TipRanks

Mon, 04 Mar 2024
OCEA Stock Quote Price and Forecast - CNN

Mon, 04 Mar 2024
Healthcare Stocks on the Move Monday: OCEA, LVTX, AIMD, RNLX, BIVI, FWBI, VANI, CDIO - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 35 (M)
Shares Float 4 (M)
Held by Insiders 71.9 (%)
Held by Institutions 13.5 (%)
Shares Short 936 (K)
Shares Short P.Month 2,960 (K)
Stock Financials
EPS -3
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.22
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -682 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow 2 (M)
Stock Valuations
PE Ratio -0.45
PEG Ratio 0
Price to Book value -0.61
Price to Sales 0
Price to Cash Flow -5.4
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android